Sporting events are no longer the most preferred target for terrorists, according to the Department of Homeland Security. Outdoor events, conferences, festivals, and other events featuring public figures are all vulnerable. And with over a thousand different-level attacks since 2015, it’s no surprise that safety and security are among the top concerns for event professionals.
Tumour Models London 2014
Increase Clinical Trial Success Rates With Predictive Tumour Models
2014-12-02 - 2014-12-04
This is the must attend meeting for preclinical oncologists, translational scientists and tumour model developers who are constantly striving to improve the predictive ability of basic oncology research and the translational success of their candidates. With an in-depth focus on cutting edge in vivo and in vitro modelling best practice, you will discover how the movement towards more physiologically relevant models will better mimic the tumour environment, better represent the patient population and help you prioritise the best drug candidates. Gain access to exclusive unpublished case study data, excellent networking sessions with senior level executives and industry-defining information on effective preclinical strategies that will improve the data interpretation from your tumour model studies and reduce failure rates of oncology clinical trials. Sound interesting? Here’s a quick snapshot of what you’ll get from attending Tumour Models London: Discover the latest developments in clinically relevant tumour models in preclinical trials and enhance your successful drug development. Learn about the most innovative immune-competent in vitro and in vivo models being used in the development cancer-immunotherapies. Harness PDX models to improve the representation of the patient population in preclinical clinical trials and enhance translational decision making. Discover the emergence of 3D modelling in drug candidate development to specifically target the tumour microenvironment. Explore the advanced pharmaco-imaging technology being used to monitor the pharmacokinetics in tumour models and improve drug efficacy. Harness in vitro modelling to investigate drug resistance and efficacy. Explore how tumour modelling can enhance the development of combination therapies. Discover the technological advancements in the field of preclinical tumour modelling and improve your preclinical predictions. Learn how introducing Next Generation sequencing into preclinical practise can improve the development of personalised medicines. Understand the importance of enhancing translational collaborations to improve drug discovery, efficacy testing and overall translational success.